ADVFN - Advanced Financial Network.
HOME» NASDAQ » T » TEVA Stock Price » TEVA Stock News

Teva Pharmaceutical Share News

 Teva Pharmaceutical Industries Limited (mm) Stock Price
TEVA Stock Price
 Teva Pharmaceutical Industries Limited (mm) Stock Chart
TEVA Stock Chart
 Teva Pharmaceutical Industries Limited (mm) Stock News
TEVA Stock News
 Teva Pharmaceutical Industries Limited (mm) Company Information
TEVA Company Information
 Teva Pharmaceutical Industries Limited (mm) Stock Trades
TEVA Stock Trades

Myriad Genetics Enters Testing Agreement With Teva Subsidiary

DOW JONES NEWSWIRES Molecular-diagnostic company Myriad Genetics Inc. (MYGN) said Wednesday it agreed to conduct BRCA1 and BRCA2 mutation testing for Cephalon Inc., a Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) subsidiary, to help assess women's risk for hereditary breast and ovarian cancer. BRCA1 and BRCA2 are human genes that belong to a class of tumor suppressor genes. Mutation of these genes has been linked to hereditary breast and ovarian cancer, according to the National Cancer Institute. Under the agreement, Myriad will assess the BRCA status in patients prior to being enrolled in a Phase I/II study. Myriad has entered into similar agreements with Abbott Laboratories (ABT), AstraZeneca PLC (AZN, AZN.LN) and BioMarin Pharmaceutical Inc. (BMRN) to provide companion diagnostic testing for clinical trial enrollment. Myriad's shares closed Wednesday at $23.56 and were inactive after hours. The stock is up 15% over the past three months. -By Ben Fox Rubin, Dow Jones Newswires; 212-416-3108;

Stock News for Teva Pharmaceutical (TEVA)
No Recent News Available

Teva Pharmaceutical and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations